Association of CYP2C9*2 with bosentan-induced liver injury.

Association of CYP2C9*2 with bosentan-induced liver injury.

Item
http://www.wikidata.org/entity/Q37325319
RUCAM in Drug and Herb Induced Liver Injury: The UpdateExploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Drug-induced liver injury: Do we know everything?Drug-induced liver injury: what was new in 2013?Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population.Managing the risk of drug-induced liver injury.Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
P2860

Association of CYP2C9*2 with bosentan-induced liver injury.

Item
http://www.wikidata.org/entity/Q37325319
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association of CYP2C9*2 with bosentan-induced liver injury.
@en
Association of CYP2C9*2 with bosentan-induced liver injury.
@nl
type
label
Association of CYP2C9*2 with bosentan-induced liver injury.
@en
Association of CYP2C9*2 with bosentan-induced liver injury.
@nl
prefLabel
Association of CYP2C9*2 with bosentan-induced liver injury.
@en
Association of CYP2C9*2 with bosentan-induced liver injury.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Association of CYP2C9*2 with bosentan-induced liver injury.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932